These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21993828)

  • 1. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability.
    Orzechowska E; Kozłowska E; Staroń K; Trzcińska-Danielewicz J
    Oncol Rep; 2012 Jan; 27(1):281-5. PubMed ID: 21993828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
    Schneider CC; Hessenauer A; Montenarh M; Götz C
    Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells.
    Hessenauer A; Montenarh M; Götz C
    Int J Oncol; 2003 Jun; 22(6):1263-70. PubMed ID: 12738992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer.
    Clarke DM; Robilotto AT; VanBuskirk RG; Baust JG; Gage AA; Baust JM
    Prostate Cancer Prostatic Dis; 2007; 10(2):175-84. PubMed ID: 17297503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
    Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
    Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
    Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS; Kemp TJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines.
    Copeland RL; Das JR; Bakare O; Enwerem NM; Berhe S; Hillaire K; White D; Beyene D; Kassim OO; Kanaan YM
    Anticancer Res; 2007; 27(3B):1537-46. PubMed ID: 17595773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CK2 inhibition induces apoptosis via the ER stress response.
    Hessenauer A; Schneider CC; Götz C; Montenarh M
    Cell Signal; 2011 Jan; 23(1):145-51. PubMed ID: 20807566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A; McDonnell TJ; Meyn RE
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
    Sun SY; Yue P; Lotan R
    Oncogene; 2000 Sep; 19(39):4513-22. PubMed ID: 11002424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
    Kyprianou N; Benning CM
    Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
    Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
    Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.